TY - JOUR
T1 - Methyladenosine Modification in RNAs
T2 - From Regulatory Roles to Therapeutic Implications in Cancer
AU - Qu, Xiaolin
AU - Zhang, Yongqiu
AU - Sang, Xianzheng
AU - Ren, Ding
AU - Zhao, Hong
AU - Wong, Stephen T.C.
N1 - Funding Information:
This work was funded by NIH R01CA238727 to H.Z. and S.T.W., NIH U01CA253553, T.T. and W.F. Chao Foundation and John S. Dunn Research Foundation to S.T.W., Houston Methodist Cornerstone Award to H.Z., and Changzheng Hospital Pyramid Talent Project (2020) of Second Military Medical University and PLA Navy No. 905 Hospital Management Project (2019 and 2021) to D.R.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/6/29
Y1 - 2022/6/29
N2 - Methyladenosine modifications are the most abundant RNA modifications, including N6-methyladenosine (m6A), N1-methyladenosine (m1A), and 2’-O-methyladenosine (m6Am). As reversible epigenetic modifications, methyladenosine modifications in eukaryotic RNAs are not invariable. Drastic alterations of m6A are found in a variety of diseases, including cancers. Dynamic changes of m6A modification induced by abnormal methyltransferase, demethylases, and readers can regulate cancer progression via interfering with the splicing, localization, translation, and stability of mRNAs. Meanwhile, m6A, m1A, and m6Am modifications also exert regulatory effects on noncoding RNAs in cancer progression. In this paper, we reviewed recent findings concerning the underlying biomechanism of methyladenosine modifications in oncogenesis and metastasis and discussed the therapeutic potential of methyladenosine modifications in cancer treatments.
AB - Methyladenosine modifications are the most abundant RNA modifications, including N6-methyladenosine (m6A), N1-methyladenosine (m1A), and 2’-O-methyladenosine (m6Am). As reversible epigenetic modifications, methyladenosine modifications in eukaryotic RNAs are not invariable. Drastic alterations of m6A are found in a variety of diseases, including cancers. Dynamic changes of m6A modification induced by abnormal methyltransferase, demethylases, and readers can regulate cancer progression via interfering with the splicing, localization, translation, and stability of mRNAs. Meanwhile, m6A, m1A, and m6Am modifications also exert regulatory effects on noncoding RNAs in cancer progression. In this paper, we reviewed recent findings concerning the underlying biomechanism of methyladenosine modifications in oncogenesis and metastasis and discussed the therapeutic potential of methyladenosine modifications in cancer treatments.
KW - cancer
KW - m6A
KW - methyladenosine
KW - oncogenesis
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85135698456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135698456&partnerID=8YFLogxK
U2 - 10.3390/cancers14133195
DO - 10.3390/cancers14133195
M3 - Review article
C2 - 35804965
AN - SCOPUS:85135698456
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 13
M1 - 3195
ER -